Advertisement
Corrigendum| Volume 25, 100196, March 2023

Download started.

Ok

Corrigendum to “Harmonization of breast cancer radiotherapy treatment planning in the Netherlands” [Tech. Innov. Patient Support Radiat. Oncol. 19 (2021) 26–32]

Open AccessPublished:January 07, 2023DOI:https://doi.org/10.1016/j.tipsro.2022.12.003
Corrigendum to “Harmonization of breast cancer radiotherapy treatment planning in the Netherlands” [Tech. Innov. Patient Support Radiat. Oncol. 19 (2021) 26–32]
Previous ArticleCorrigendum to “Evaluation of image-guided and surface-guided radiotherapy for breast cancer patients treated in deep inspiration breath-hold: A single institution experience” [Tech. Innov. Patient Support Radiat. Oncol. 21 (2022) 51–57]
Next ArticleCorrigendum to “Surface-guided radiotherapy for lung cancer can reduce the number of close patient contacts without compromising initial setup accuracy” [Tech. Innov. Patient Support Radiat. Oncol. 20 (2021) 61–63]
      The authors regret that the following Patient Consent Statement was missing from the above article:
      Patient Consent
      The research was conducted on anonymized patient data according to Dutch data protection and privacy legislation.
      The authors would like to apologise for any inconvenience caused.

      Article info

      Publication history

      Published online: January 07, 2023

      Identification

      DOI: https://doi.org/10.1016/j.tipsro.2022.12.003

      Copyright

      © 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy & Oncology.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      Linked Article

      • Harmonization of breast cancer radiotherapy treatment planning in the Netherlands
        Technical Innovations and Patient Support in Radiation Oncology Vol. 19
        • Preview
          Postoperative breast cancer radiotherapy (RT) reduces the risk of local recurrence with a factor of 3–4 [1]. In The Netherlands the standard schedule for breast radiotherapy has been 15 fractions of 2.67 Gy since 2013, based on 10-year follow-up results of the START B trial [2]. When designing an RT plan, a continuous trade off between optimal dose to the target versus optimal sparing of organs at risk (OAR) needs to be made. As the relationship between dose-volume parameters, local control and side-effects is not very clear, and because the acceptance of a local recurrence risk and side effects differ per physician and per patient, a wide practice variation exists in the trade-offs made.
        • Full-Text
        • PDF
        Open Access

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX